Cargando…
Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
Oral squamous cell carcinoma (OSCC) is often associated with metastatic disease and a poor 5 year survival rate. Patients diagnosed with small tumours generally have a more favourable outcome, but some of these small tumours are aggressive and lead to early death. To avoid harmful overtreatment of p...
Autores principales: | Magnussen, Synnøve, Rikardsen, Oddveig G., Hadler-Olsen, Elin, Uhlin-Hansen, Lars, Steigen, Sonja E., Svineng, Gunbjørg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084992/ https://www.ncbi.nlm.nih.gov/pubmed/24999729 http://dx.doi.org/10.1371/journal.pone.0101895 |
Ejemplares similares
-
Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014) -
Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma
por: Rikardsen, Oddveig G., et al.
Publicado: (2015) -
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
por: Magnussen, Synnove Norvoll, et al.
Publicado: (2017) -
Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013) -
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)